Amundi Grows Position in Abbott Laboratories $ABT

Key Points

• Amundi increased its Abbott Laboratories stake by 20.2% in the second quarter, adding 1.5 million shares to own 8.9 million shares valued at approximately $808 million. Institutional investors collectively hold 75.18% of Abbott’s outstanding stock.
• Abbott reported quarterly adjusted EPS of $1.31, exceeding estimates by $0.03, while revenue rose 13% year over year to $12.59 billion. The company guided for fiscal 2026 EPS of $5.45–$5.60.
• Analysts maintain a favorable outlook, with the stock carrying a consensus “Moderate Buy” rating and an average price target of $119.50 versus its recent $108.29 price. Abbott also pays a $2.52 annualized dividend, yielding about 2.3%.

Amundi grew its position in Abbott Laboratories (NYSE:ABT - Free Report) by 20.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,906,252 shares of the healthcare product maker's stock after acquiring an additional 1,499,291 shares during the quarter. Amundi owned 0.51% of Abbott Laboratories worth $808,142,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Freemont Management S.A. increased its holdings in Abbott Laboratories by 197.2% during the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker's stock worth $1,341,000 after purchasing an additional 7,100 shares during the period. Thrivent Financial for Lutherans lifted its holdings in shares of Abbott Laboratories by 24.3% in the 4th quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker's stock worth $30,931,000 after buying an additional 48,286 shares during the period. Aureus Asset Management LLC grew its position in shares of Abbott Laboratories by 25.0% during the 1st quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker's stock worth $34,078,000 after buying an additional 66,422 shares in the last quarter. North Dakota State Investment Board bought a new position in shares of Abbott Laboratories during the 4th quarter worth $7,439,000. Finally, Thompson Investment Management Inc. increased its stake in shares of Abbott Laboratories by 786.0% during the second quarter. Thompson Investment Management Inc. now owns 14,061 shares of the healthcare product maker's stock valued at $1,276,000 after buying an additional 12,474 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Price Performance

ABT opened at $108.29 on Tuesday. The firm has a market capitalization of $187.38 billion, a PE ratio of 35.05, a price-to-earnings-growth ratio of 2.01 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The business's 50-day moving average is $104.74 and its two-hundred day moving average is $100.00. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. During the same period in the prior year, the firm posted $1.26 earnings per share. The company's quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were given a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories's dividend payout ratio (DPR) is presently 81.55%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ABT shares. Robert W. Baird began coverage on shares of Abbott Laboratories in a research note on Wednesday, July 1st. They issued an "outperform" rating and a $121.00 price objective for the company. Piper Sandler reissued an "overweight" rating and set a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Bank of America reduced their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $130.00 price target on shares of Abbott Laboratories in a research report on Friday, July 17th. Finally, Wolfe Research upgraded shares of Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 price objective on the stock in a research note on Thursday, August 13th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat.com, Abbott Laboratories currently has an average rating of "Moderate Buy" and a consensus price target of $119.50.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.